Clinical Trial Update: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 pediatric MATCH trial evaluating IDH1-mutant tumors for response to ivosidenib; results for recurrent and refractory solid tumors, lymphomas, and histio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Ewing Sarcoma
• Hepatoblastoma
• Langerhans Cell Histiocytosis
• Medulloblastoma
• Neuroblastoma
• Osteosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-25